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Platelet activation is associated with the phospho~lation of a number of platelet proteins at tyrosine residues. The significance of this IS unknown. 
Here we have investigated the effects of two tyrosine kinase Inhibitors, methyl 2.5dthydroxycinnamate and genistein. on thrombin-evoked protein 
tyrosine phosphorylation and Ca*’ signal generatton in fura-2-loaded human platelets. Both compounds inhibited thrombin-evoked tyrosine 
phosphorylation and reduced the elevatton of [Caz’lI in the presence, but not the absence, of external Cal+. This suggested a selectrve inhibition 
of thrombin-evoked Ca’+ entry but not release from internal stores. Both compounds also reduced thrombin-evoked Mn*” entry. In contrast, 
selective blockade of protein kinase C with Ro 31/822&002 potentiated the thrombin-evoked Ca*’ signal. These data are compatible wtth a role 
for protein tyrosine phospho~lation contributing to thrombin-evoked Ca’+ entry in human platelets. 
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1. INTRODUCTION 
Agonist-stimulation of platelet plasma membrane re- 
ceptors results in the Phospholipase C-mediated metab- 
olism of inositol phospholipids and the production of 
inositol 1 ,fW-isphosphate (InsP,) and diacylglycerol 
(DAG) [l-3]. InsP, is responsible for the mobilisation 
of Ca” from the internal stores 141. The mechanism 
which accounts for the sustained phase of Ca2’ entry 
following agonist-stimulation remains unclear. 
During platelet activation many proteins are 
phospho~lated at tyrosine residues (e.g. [5-9]), al- 
though the functional si~ificance of this is uncertain. 
Increased tyrosine phosphorylation may be an integral 
component of platelet signal transduction [lo]. Platelets 
possess everal protein-tyrosine kinases such as the cel- 
lular SIC andfyn gene products [l l-l 31. The cytoplasmic 
tyrosine kinase pp60”“’ is particularly abundant in 
platelets [7,13]. 
Evidence is now emerging that many elements of the 
signal transduction pathway interact at specific recogni- 
tion sites, termed SH2-domains [14,15] . These regions 
are found on many different substrates, and permit the 
association of substrate with receptors that possess in- 
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trinsic tyrosine kinase activity. For example, Phospho- 
lipase C-y has been found to associate with, and be 
phosphorylated by, several tyrosine kinase receptor sys- 
tems [l&19]. It is therefore possible that the SHZ-do- 
mains of the cytoplasmic tyrosine kinases present in 
platelets. such as src and fyn. are also involved in the 
control of PLC-y activity 120,211. 
It has recently been suggested that the cytosolic and 
intracellular store calcium concentration may antago- 
nistically control platelet tyrosine phosphorylation [22]. 
In this model elevated cytosolic calcium is proposed to 
activate a tyrosine kinase leading to phosphorylation of 
certain platelet proteins and the promotion of calcium 
entry. A calcium replete internal store is proposed to 
activate a tyrosine phosphatase such that store refilling 
would reduce tyrosine phosphorylation and. therefore, 
Ca” entry. 
In many cell types, including plateiets, it has been 
demonstrated that the depletion of the intracellular 
Ca” stores promotes divalent cation entry [23-261, al- 
though the nature of the coupling from intracellular 
Ca’+ stores to plasma membrane remains unclear. It has 
been proposed that cytochrome P-450, or one of its 
metabohtes, might couple store depletion to Ca2+ entry 
in human platelets [27] and other cells [Z&J This model 
was proposed on the basis of inhibition of Mn’+ and 
Ca2+ entry by inhibitors of cytochrome P-450. How- 
ever, our previous work suggests against a role for the 
cytochrome in mediating agonist-evoked ivalent cat- 
ion entry [29,30]. A model in which stored and cytosolic 
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Ca*+ exert an antagonistsic ontrol over Ca*+ entry is 
functionally indistinguishable from store-regulated 
entry and might provide an alternative explanation for 
this phenomenon in platelets. 
To assess the possible role of tyrosine phosphoryla- 
tion in agonist-evoked Ca*+ signal generation we have 
investigated the effects of the inhibitors of tyrosine ki- 
nases, genistein [3 1,321 and methyl 2,5dihydroxycinna- 
mate [33,34], using fura-2-loaded human platelets. 
These inhibitors were compared with Ro 31/8220-002 
and Ro 31/7549-001, selective inhibitors of protein ki- 
nase C [35]. To confirm the tyrosine kinase inhibitors 
were effective in platelets, the actions of methyl 2,5- 
dihydroxycinnamate and genistein on protein tyrosine 
phosphorylation were assessed by gel electrophoresis 
and Western blotting with a specific anti-phosphoty- 
rosine antibody. 
2. EXPERIMENTAL 
Fura-2-loaded human platelets were prepared as previously de- 
scribed [29]. Changes in intracellular free calcium concentration, 
[Ca”],, were monitored using the 3401380 nm fluorescence ratio. In 
experiments involving genistein or diadzein, changes in [Ca”], were 
judged from the 340/380 nm ratio since both compounds interfered 
with fura- fluorescence. Genistein was without effect on agonist- 
evoked Ca” signals for upto 2 min of incubation, so controls were 
performed with inhibitor applied immediately prior to addition of 
agonist. Methyl 2,5-dihydroxycinnamate had negligible effects on flu- 
orescence such that the 340/380 nm ratio could be calibrated in terms 
of [Ca”], as previously described [36]. 
Tyrosine phosphorylation was detected by gel electrophoresis and 
Western blotting [9]. Platelet stimulation was terminated by the addi- 
tion of an equal volume of Laemmli’s buffer [37] with 10% 2-mercap- 
toethanol followed by heating for 5 mins at 95°C. One-dimensional 
SDS electrophoresis was performed with 8% polyacrylamide mmigels 
and separated proteins were electrophoretically transferred, for 15 h 
at 1.5 A, onto Immobilon (Millipore) membranes for subsequent 
probing. The blots were incubated for 1 h with 5% (w/v) milk protein 
in Tris-buffered saline with 0.02% Tween (TBST) to block residual 
protein binding sites. Immunodetection of tyrosine phosphorylation 
was achieved using a specific anti-phosphotyrosine monoclonal mur- 
ine antibody (055321, UBI, USA) diluted 1:2000 in TBST, for 1 h. The 
primary antibody was removed, and the blots washed six times in 
TBST. To detect he primary antibody the blots were incubated with 
HRP-conjugated ovine anti-mouse antibody (NA93 1, Amersham) di- 
luted 1:6000 in TBST. washed six times in TBST and exposed to ECL 
reagents for 1 min. Blots were exposed to pre-flashed photographic 
film for l-5 min. 
2.1. Materials 
Methyl 2,5_dihydroxycinnamate was a kind gift of Dr. A. Hudson, 
Wellcome Research Laboratories, Beckenham, UK. Ro 31/8220-002 
and Ro 31/75499001 were kindly provided by Dr. T.J. Hallam, Roche 
Research Centre, Welwyn Garden City, UK. Apyrase. aspirin, EGTA 
and Bovine thrombin were from Sigma (Poole, Dorset, UK). All other 
reagents were of analytical grade. 
3. RESULTS AND DISCUSSION 
3.1. Effects of methyl 2,5-dihydroxycinnamate 
Fig. la shows that preincubation for 30 min with the 
tyrosine kinase inhibitor methyl 2,5_dihydroxycinna- 
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Fig. 1. Effect of methyl 2,5-dihydroxycinnamate on [Ca”], rises and 
Mn” entry evoked by thrombin in human platelets. Fura-2-loaded 
platelets were incubated with 1 pg/ml methyl 2,5_dihydroxycinnamate 
(dashed lines) or the vehicle, DMSO (solid lines) as control, for 30 
mins at 37°C in stirred cuvettes. At the time of experiments either 1 
mM Ca’+ (a), 1 mM EGTA (b) or 1 mM Ca” and 200pM Mn” (c) 
were added to cells. Thrombin (1 U/ml), was added as shown. The 
3401380 nm ratio was calibrated in terms of [Ca”], (top two panels). 
In the bottom panel the trace shows quench of fura- fluorescence with 
excitation at 360 nm. confirming divalent cation entry. 
mate (1 pg/ml), a stable analogue of erbstatin, reduced 
the Ca” elevation evoked by thrombin (1 U/ml) in me- 
dium containing 1 mM Ca2+ from 981 + 135 nM to 
306 * 59 nM (S.E.M., IZ = lo), at the initial peak. This 
difference was statistically significant (Student’s t-test, 
difference of the means, 0.001 > P). 
The possibility that the inhibition of tyrosine phos- 
phorylation by methyl 2,5_dihydroxycinnamate may in- 
terfere with the production of inositol 1,4,5-tris- 
phosphate (InsP,), through inhibition of PLC-y, was 
tested for by examination of the release of the intracel- 
lular Ca*’ stores. A preincubation with methyl 2,5-dihy- 
droxycinnamate (1 ,&ml; 30 min) had little effect upon 
the release of Ca” from the internal stores, as indicated 
by experiments performed in the presence of 1 mM 
EGTA (Fig. lb). The initial, peak elevation of [Ca”], 
was 153 ? 19 nM after preincubation with methyl 2,5- 
dihydroxycinnamate (100 PM; 30 min) and 193 + 14 
243 
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Fig. 2. Effects of genistein or diadzein on thrombin-evoked [Ca”lI rises 
and Mn’* entry in human platelets. Fura-Ztoaded platetets were incu- 
bated for 30 min, in stirred cuvettes at 37°C. with either 100 pM 
genistein, feft hand panels, or la0 @vZ diadzein. right hand panefs 
(dashed lines) or the vehicle, DMSG, as control {solid lines). At the 
time of experiments either 1 mM Ca” (a) and (d), 1 mM EGTA (b) 
and (e) or 1 mM Ca” and 200 PM Mn’+ (c) and (f) were added. All 
other details are as for Fig. 1, except that changes in [Ca”], were 
judged from the 340/380 nm ratio. 
nM in controls (S&M., n = 10). This difference was not 
significant (Student’s t-test, difference of the means, 
0.5 > P > 0.1). 
The lack of a significant effect of methyl 2.5-d&y- 
droxycinnam~te on the release of Ca”” from the intra- 
cellular stores suggests that the effect of the inhibitor on 
PLC-y is small. Therefore, in platelets, at least, tyrosine 
kinase-mediated regulation of PLC-y is unlikely to be 
an important contribution to the initial discharge of the 
internal Ca*’ stores. These data suggest that methyl 
2,5~dihydroxy~nnamate is refatively selective at inhibit- 
ing thrombin-evoked Ca2’ entry. 
The inhibition of divalent cation influx was con- 
firmed by reduction of thrombin-evoked Mn2+ quench 
of fura- fluorescence in medium containing 1 mM Ca2+ 
and 200 PM Mn” (Fig. 1~). 
3.2. Effects of genistein and diadzein 
Fig. 2 shows results obtained with another tyrosine 
kinase inhibitor, genistein, and its inactive analogue, 
diadzein. Preincubation with genistein (100pM; 30 min) 
reduced the ~rombi~-evoked rise in [Ca2’],, as indicated 
by the 340~3g~ nm fiuorescence ratio, in medium con- 
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Fig. 3, Effect of the selective protein kinase C inhibitor, Ro 3%322@- 
002, on the rise in iCar*], evoked by thrombin in human platelets. 
Fura-2-loaded platelets were incubated with 3 +& Ro 3118220-002 
(dashed line) or the vehicle (solid line) for 20 min in stirred cuvettes 
at 37°C before addition of 1 U/ml thrombin. The 340/380 nm fluores- 
cence ratio was cahbrated in terms of [Ca’+],. 
taining 1 mM Ca” by about 35% (Fig. 2a), at the peak 
of response, as compared with controls. Responses in 
medium containing 1 mM EGTA were unaffected by a 
similar preincubation with genistein (Fig. 2b), indicat- 
ing that the inhibitor was without effect on the release 
of Ca2’ from the tntracelfular stores, The inhibition of 
agonist-evoked ivalent cation entry by genistein was 
further demonstrated by the finding that genistein re- 
duced the thrombin-evoked Mn2’ quench of fura- flu- 
orescence in medium containing 200 PM Mn2’ (Fig. 2~). 
Preincubation with diadzein (100pM; 30 min) was with- 
out effect on thrombin-evoked Ca” entry, release of 
Ca” from internal stores and &in’+ entry (Fig. 2d, e and 
f, respectively). 
3.3. Effects of the speczjic protein kinase C inhibitor 
Although these results suggest that inhibition of tyro- 
sine kinase activity selectively reduces thrombin-evoked 
Ca’* entry, the selectivity of presently available inhib- 
itors is uncertain, and effects on other kinases cannot 
be excluded. However, the results presented here are 
unlikely to be due to inhibition of protein kinases A, C 
or G, all of which have ~nh~b~to~ effects on Ca” signal 
generation in platelets [38]. ff these kinases were being 
inhibited, Ca2’ signals might be expected, if anything, 
to be potentiated, rather than reduced. This point is 
addressed in Fig. 3. Preincubation with the selective 
protein kinase C inhibitor Ro 3X3220-002 (3 yM; 20 
mint slightly, but not si~n~eantly, decreased the peak 
[Ca”], rise evoked by thrombin, 1283 1- 97 nM com- 
pared with 1484 ? 1.57 nM in controls (S.E.M., n = 3, 
Student’s C-test, difference of the means 0.5 > P > O.l), 
and significantly slowed the subsequent decline of the 
maintained elevated [Ca”], phase, f I 12 + 98 nM com- 
pared with 715 t 103 nM (S.E.M., n = 3, 0.05 > P>* at 
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Fig. 4. Effects of genistein, diadzein and methyl 2,5-dihydroxycinnamate on changes of tyrosine phosphorylation in thrombin stimulated human 
platelets. 100 ~1 ahquots were taken from a cuvette of stirred, fura-2-loaded platelet suspension at 10 s before agonist (-lo), and 15, 30 and 60 
s after addition of thrombin (1 U/ml). Platelet suspension had been preincubated for 30 min at 37°C in stirred cuvettes with either methyl 
2,5dihydroxycinnamate (methyl 2,5-dhc) (1 @ml) (a) (four right-hand lanes), genistein (100 PM) (b) (four left-hand lanes) or diadzein (100 PM) 
(c) {four right-hand lanes), or the vehicle, DMSO, (all other lanes) as control. Proteins were analysed by 8% SDS-PAGE and subsequent Western 
blotting with a specific anti-phosphotyrosine antibody as described in section 2. 
3 min post stimulation. Similar results were obtained 
with another selective PKC inhibitor. Ro 31/7549-001. 
The inhibition of agonist-evoked Ca” and Mn2+ 
entry by the tyrosine kinase inhibitors suggests that 
tyrosine phosphorylation may be a component of plate- 
let Ca” signal generation. However, effects other than 
on tyrosine phosphorylation cannot be ruled out. To 
assess the effectiveness of the tyrosine kinase inhibitors 
used here against agonist-evoked tyrosine phosphoryla- 
tion in fura-2-loaded human platelets, samples were 
taken during the timecourses of fluorescence experi- 
ments and protein tyrosine phospho~lation deter- 
mined. Typical gels are shown in Fig. 4. A 30 min 
incubation with methyl 2,5-dihydroxycinnamate (1 ,I.& 
ml) or genistein (100 PM), (Fig. 4a and b), reduced 
thrombin-stimulated protein tyrosine phosphorylation, 
with inhibition most evident at certain bands (eg. geni- 
stein most strongly inhibited tyrosine phosphorylation 
245 
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of proteins 97-200KD; methyl 2,5_dihydroxycinnamate 
inhibited two specific bands of 97KD and approxi- 
mately 140KD. Fig. 4a and b). Diadzein (100 ,uM), the 
inactive analogue, was without significant effect on 
thrombin-evoked tyrosine phosphorylation (Fig. 4~). 
3.5. Conclusions 
In conclusion, we have demonstrated that two tyro- 
sine kinase inhibitors. methyl 2,5-dihydroxycinnamate 
and genistein, effectively reduced thrombin-evoked pro- 
tein tyrosine phosphorylation in human platelets. Both 
compounds inhibited thrombin-evoked Ca*+ and Mn” 
influx whilst having little effect on thrombin-evoked 
release of Ca’+ from the intracellular stores. These data 
are compatible with a role for protein tyrosine phospho- 
rylation in the generation of agonist-evoked Ca” entry 
in human platelets. 
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